This is a nonrandomized, open-label, multicenter rollover study for patients who received
futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib
study.
Additional locations may be listed on ClinicalTrials.gov for NCT06506955.
See trial information on ClinicalTrials.gov for a list of participating sites.
TAS-120-404 is a nonrandomized, open-label, multicenter rollover study for patients who
received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored
futibatinib study.
Patients who are still receiving futibatinib as monotherapy or as combination therapy,
are deriving clinical benefit with no undue risk as assessed by the investigator, and
have not met any of the antecedent protocol-specific discontinuation criteria are
eligible to participate.
Lead OrganizationTaiho Pharmaceutical Company Limited
